{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:08:20Z","timestamp":1759190900271,"version":"3.44.0"},"reference-count":52,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:00:00Z","timestamp":1759017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["22K06707"],"award-info":[{"award-number":["22K06707"]}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Thrombosis, a critical condition that can have severe consequences, such as myocardial infarction and cerebral infarction, can be induced by steroid drugs. Although the mechanisms for inducing thrombosis are known for some types of steroid drugs, much remains unknown about the differences in the tendency and mechanisms for thrombosis. Methods: To address this knowledge gap, we analyzed the relationship between thrombosis and steroid use by utilizing the U.S. Food and Drug Administration Adverse Event Reporting System database. From the database, we extracted demographic and drug information and information on reported adverse events from 2004 to 2024. We characterized drugs according to physiological function, receptor specificity, and Anatomic Therapeutic Chemical classification and calculated the proportion of steroid drugs that were likely to induce thrombosis. Results: Among steroid drugs, sex hormones such as androgens, progestogens, and estrogens appeared to have particularly high potential for causing thrombotic events. Results of principal component analysis and cluster analysis indicated that sex hormone preparations were associated with an increased risk of venous thrombosis. In addition, cardiovascular medications and mineralocorticoids, which are used to treat diseases of major organs, showed a tendency to induce large-vessel occlusions. Conclusions: These findings may be useful for selecting steroid drugs for patients who are at risk for similar adverse effects.<\/jats:p>","DOI":"10.3390\/ph18101463","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T10:49:34Z","timestamp":1759142974000},"page":"1463","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Steroid-Induced Thrombosis: A Comprehensive Analysis Using the FAERS Database"],"prefix":"10.3390","volume":"18","author":[{"given":"Ayame","family":"Watanabe","sequence":"first","affiliation":[{"name":"Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo 204-8588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5773-991X","authenticated-orcid":false,"given":"Yoshihiro","family":"Uesawa","sequence":"additional","affiliation":[{"name":"Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo 204-8588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11060-009-0057-4","article-title":"The role of steroids in the management of brain metastases: A systematic review and evidence-based clinical practice guideline","volume":"96","author":"Ryken","year":"2010","journal-title":"J. Neuro-Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40262-024-01419-7","article-title":"Pharmacokinetics and pharmacodynamics of systemic corticosteroids in autoimmune and inflammatory diseases: A review of current evidence","volume":"63","author":"Ezzafzafi","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejmech.2017.03.054","article-title":"Quest for steroidomimetics: Amino acids derived steroidal and nonsteroidal architectures","volume":"133","author":"Ahmad","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ronchetti, S., Ayroldi, E., Ricci, E., Gentili, M., Migilorati, G., and Riccardi, C. (2021). A glance at the use of glucocorticoids in rare inflammatory and autoimmune diseases: Still an indispensable pharmacological tool?. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.613435"},{"key":"ref_5","first-page":"826","article-title":"Symposium S-2: The current status of thromboembolism caused by use of female sex hormones in Japan","volume":"48","author":"Sugiura","year":"2016","journal-title":"Shinzo"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zhang, G.-Q., Chen, J.-L., Luo, Y., Mathur, M.B., Anagnostis, P., Nurmatov, U., Talibov, M., Zhang, J., Hawrylowicz, C.M., and Lumsden, M.A. (2021). Menopausal hormone therapy and women\u2019s health: An umbrella review. PLoS Med., 18.","DOI":"10.1371\/journal.pmed.1003731"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5582\/bst.2021.01418","article-title":"Update on hormone therapy for the management of postmenopausal women","volume":"16","author":"Pan","year":"2022","journal-title":"Biosci. Trends"},{"key":"ref_8","first-page":"606","article-title":"Postmenopausal Osteoporosis and Estrogen","volume":"68","author":"Nelson","year":"2003","journal-title":"Am. Fam. Physician"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"a031211","DOI":"10.1101\/cshperspect.a031211","article-title":"Regulation of bone metabolism by sex steroids","volume":"8","author":"Khosla","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Timmermans, S., Souffriau, J., and Libert, C. (2019). A general introduction to glucocorticoid biology. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01545"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Bond, P., Smit, D.L., and Ronde, W.D. (2022). Anabolic\u2013androgenic steroids: How do they work and what are the risks?. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1059473"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.2147\/JMDH.S439384","article-title":"The uses of anabolic androgenic steroids among athletes; its positive and negative aspects-a literature review","volume":"16","author":"Wenbo","year":"2023","journal-title":"J. Multidiscip. Healthc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: Population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"ref_14","unstructured":"Ministry of Health, Labour and Welfare of Japan (2007). Manual for Serious Adverse Drug Reactions by Disease: Thrombosis (Thrombo-embolism, Embolism, Infarction), Ministry of Health, Labour and Welfare."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ayyoub, S., Orriols, R., Oliver, E., and Ceide, O.T. (2023). Thrombosis models: An overview of common in vivo and in vitro models of thrombosis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032569"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.thromres.2020.04.035","article-title":"Arterial and venous thrombosis: What\u2019s the link? A narrative review","volume":"191","author":"Delluc","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Donadini, M.P., Calcaterra, F., Romualdi, E., Ciceri, R., Cancellara, A., Lodigiani, C., Bacci, M., Bella, S.D., Ageno, W., and Mavilio, D. (2025). The link between venous and arterial thrombosis: Is there a role for endothelial dysfunction?. Cells, 14.","DOI":"10.3390\/cells14020144"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Macleod, C., Hadoke, P.W.F., and Nixon, M. (2021). Glucocorticoids: Fuelling the fire of atherosclerosis or therapeutic extinguishers?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147622"},{"key":"ref_19","unstructured":"FDA (2025, September 02). FDA Adverse Event Reporting System (FAERS), Available online: https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/107602960401000308","article-title":"Effect of age on oral contraceptive\u2013induced venous thrombosis","volume":"10","author":"Girolami","year":"2004","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"528","DOI":"10.7326\/0003-4819-126-7-199704010-00005","article-title":"Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation","volume":"126","author":"Ridker","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: Results of the MEGA case-control study","volume":"339","author":"Helmerhorst","year":"2009","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1210\/jc.2015-2237","article-title":"Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis","volume":"100","author":"Mohammed","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.thromres.2020.05.008","article-title":"Estrogen and thrombosis: A bench to bedside review","volume":"192","author":"Nayak","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Dupuis, M., Severin, S., Noirrit-Esclassan, E., Arnal, J.-F., Payrastre, B., and Val\u00e9ra, M.-C. (2019). Effects of Estrogens on Platelets and Megakaryocytes. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20123111"},{"key":"ref_26","unstructured":"Medscape (2025, September 02). Menopause and Hormone Therapy. Available online: https:\/\/emedicine.medscape.com\/article\/276107-overview."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1111\/jog.15795","article-title":"Real-world practice of estrogen and progestogen prescriptions in menopausal women in Japan: A descriptive study using a Japanese claims database","volume":"49","author":"Inayama","year":"2023","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.maturitas.2014.07.009","article-title":"Systemic progesterone therapy\u2014Oral, vaginal, injections and even transdermal?","volume":"79","author":"Ruan","year":"2014","journal-title":"Maturitas"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"834","DOI":"10.21037\/tau.2016.07.10","article-title":"Pharmacology of testosterone replacement therapy preparations","volume":"5","author":"Shoskes","year":"2016","journal-title":"Transl. Androl. Urol."},{"key":"ref_30","first-page":"203","article-title":"Steroids: Pharmacology, complications, and practice delivery issues","volume":"14","author":"Kaye","year":"2014","journal-title":"Ochsner J."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Glueck, C.J., Goldenberg, N., and Wang, P. (2018). Testosterone therapy, thrombophilia, venous thromboembolism, and thrombotic events. J. Clin. Med., 8.","DOI":"10.3390\/jcm8010011"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"20150202","DOI":"10.1098\/rsta.2015.0202","article-title":"Principal component analysis: A review and recent developments","volume":"374","author":"Jolliffe","year":"2016","journal-title":"Philos. Trans. R. Soc. A"},{"key":"ref_33","first-page":"1190","article-title":"Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation? A nationwide population-based cohort study","volume":"30","author":"Chao","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Lai, K.-C., Chen, S.-J., Lin, C.-S., Yang, F.-C., Lin, C.-L., Hsu, C.-W., Huang, W.-C., and Kao, C.-H. (2018). Digoxin and amiodarone on the risk of ischemic stroke in atrial fibrillation: An observational study. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00448"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijcard.2015.04.031","article-title":"Digoxin in patients with atrial fibrillation and heart failure: A meta-analysis","volume":"188","author":"Bavishi","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Everitt, B.S., Landau, S., Leese, M., and Stahl, D. (2011). Cluster Analysis, Wiley-Blackwell. [5th ed.].","DOI":"10.1002\/9780470977811"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s11886-023-01935-1","article-title":"Testosterone replacement therapy and cardiovascular disease: Balancing safety and risks in hypogonadal men","volume":"25","author":"Blackwell","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"114582","DOI":"10.1016\/j.addr.2022.114582","article-title":"Novel drug delivery systems for the management of dry eye","volume":"191","author":"Nagai","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/BF03261981","article-title":"Effect of competition bias in safety signal generation: Analysis of a research database of spontaneous reports in France","volume":"35","author":"Pariente","year":"2012","journal-title":"Drug Saf."},{"key":"ref_40","unstructured":"(2025, September 02). PubChemPy. Available online: https:\/\/github.com\/mcs07\/pubchempy."},{"key":"ref_41","unstructured":"(2025, September 02). Molecular Operating Environment. Available online: https:\/\/www.chemcomp.com\/en\/Products.htm."},{"key":"ref_42","unstructured":"National Library of Medicine (2025, June 18). DailyMed, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/."},{"key":"ref_43","unstructured":"(2025, September 02). Introductory Guide for Standardised MedDRA Queries (SMQs) Version 27.1. Available online: https:\/\/www.jmo.pmrj.jp\/download\/2361."},{"key":"ref_44","unstructured":"(2025, September 02). Introductory Guide MedDRA Version 27.1. Available online: https:\/\/www.jmo.pmrj.jp\/download\/2360."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1469-1809.1955.tb01285.x","article-title":"The estimation and significance of the logarithm of a ratio of frequencies","volume":"20","author":"Haldane","year":"1956","journal-title":"Ann. Hum. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/biomet\/43.3-4.461","article-title":"On estimating binomial response relations","volume":"43","author":"Anscombe","year":"1956","journal-title":"Biometrika"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/1740774513485311","article-title":"Summarizing the Incidence of Adverse Events Using Volcano Plots and Time Intervals","volume":"10","author":"Zink","year":"2013","journal-title":"Clin. Trials"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Kan, Y., Nagai, J., and Uesawa, Y. (2025). Evaluation of antibiotic-induced taste and smell disorders using the FDA adverse event reporting system database. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-88958-2"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Qi, Y., Li, J., Lin, S., Wu, S., Chai, K., Jiang, X., Qian, J., and Jiang, C. (2024). A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-62356-w"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Duan, Y., Wang, Y., Lu, S., Zeng, M., Liu, L., Dai, Q., and Yin, R. (2024). Adverse event profile of albumin-bound paclitaxel: A real-world pharmacovigilance analysis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1448144"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Liu, Q., Cui, Z., Deng, C., Yang, C., and Shi, T. (2024). A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1485190"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2307\/2529943","article-title":"Unresolved problems in cluster analysis","volume":"35","author":"Everitt","year":"1979","journal-title":"Biometrics"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/10\/1463\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:02:26Z","timestamp":1759143746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/10\/1463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,28]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ph18101463"],"URL":"https:\/\/doi.org\/10.3390\/ph18101463","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,28]]}}}